Apomorphine Injection

Introduction Overview

Generic Name

apomorphine injection

Brand Name

Apokyn

Dosage Form

subcutaneous injection (injection pen)

Drug Class

dopaminergic antiparkinsonism agents

Pharmacokinetics

Absorption

Apomorphine is administered subcutaneously and exhibits rapid absorption from the injection site, with onset of action occurring within approximately 10 minutes and peak clinical effects within 20 to 60 minutes. The subcutaneous route bypasses the gastrointestinal tract, avoiding first-pass metabolism and providing prompt central nervous system availability. Factors such as injection site blood flow and patient-specific characteristics may influence absorption kinetics.

Distribution

Following absorption, apomorphine exhibits wide distribution, with a volume of distribution indicative of extensive tissue penetration. It readily crosses the blood-brain barrier to exert dopaminergic effects in the central nervous system, particularly in basal ganglia structures affected by Parkinson’s disease. It is also moderately bound to plasma proteins, which may affect its pharmacokinetic profile.

Metabolism

Apomorphine undergoes extensive hepatic metabolism primarily via conjugation pathways including glucuronidation and sulfation, as well as oxidative metabolism by cytochrome P450 enzymes. Its metabolites are generally inactive. The metabolic transformation is rapid, contributing to the relatively short duration of action. Hepatic impairment may alter metabolism and increase systemic exposure, requiring careful dose adjustments.

Elimination

The elimination half-life of apomorphine is approximately 30 to 90 minutes following subcutaneous administration. Excretion primarily occurs via the renal route as metabolites, with minimal unchanged drug detected in urine. Biliary excretion is minimal. Renal impairment can affect clearance, necessitating cautious use and monitoring in such patients.

Dosage Forms

Adults

Apokyn is supplied as a sterile injectable solution for subcutaneous administration in an injection pen device, with concentrations allowing dosing in milligram equivalents, typically measured in mL on the pen for dosing precision. The usual adult dosing initiates under medical supervision with an initial subcutaneous dose of 2 mg (0.2 mL) administered during 'off' episodes of Parkinson's disease. Dose titration may proceed in 1-2 mg increments to an effective dose, not exceeding a maximum of 6 mg (0.6 mL) per single dose and 20 mg (2 mL) per day. Doses should be spaced by at least 2 hours, with a typical frequency of 3 injections per day up to 5 times daily if needed.

Adolescents

Safety and efficacy of Apokyn in pediatric patients have not been established, and its use in children is not recommended due to lack of data; therefore, dosing guidelines for adolescents are not defined.

Special Populations

In special populations such as those with hepatic or renal impairment, caution is advised due to altered metabolism and clearance that may increase systemic exposure; dosage adjustments and close monitoring are recommended. Elderly patients may be more susceptible to orthostatic hypotension and CNS side effects. Pregnancy and breastfeeding data are insufficient; thus, use is advised only if clearly needed and under medical supervision. Patients with comorbidities such as cardiovascular disease, electrolyte abnormalities, or history of arrhythmias require careful assessment prior to initiating therapy to avoid exacerbation of adverse effects.

Mechanism Of Action

Apomorphine, the active ingredient in Apokyn, is a potent dopamine receptor agonist that primarily stimulates dopamine D1 and D2 receptor subtypes in the central nervous system. By mimicking endogenous dopamine, it compensates for the dopaminergic deficit observed in Parkinson’s disease, particularly in the striatum where motor function is regulated. This stimulation restores dopaminergic neurotransmission, improving motor control during 'off' episodes when levodopa effects wane.

At the molecular level, apomorphine binds to dopamine receptors on postsynaptic neurons, activating intracellular signaling cascades that modulate neuronal excitability and synaptic plasticity, leading to enhanced motor function. It also affects pre-synaptic receptors, modulating dopamine release and reuptake mechanisms.

Unlike levodopa, which is a dopamine precursor requiring enzymatic conversion, apomorphine acts directly as an agonist, providing rapid onset of action suitable for acute 'off' episodes. Its administration bypasses gastrointestinal metabolism, overcoming delayed absorption issues.

Clinical studies demonstrate that subcutaneous apomorphine injections rapidly reverse motor fluctuations in advanced Parkinson’s patients. Comparative research indicates its efficacy as a rescue therapy complementary to other dopaminergic agents, though its short half-life necessitates repeated dosing. The unique pharmacologic profile offers advantages in managing unpredictable motor symptoms associated with PD progression.

Pharmacological Actions

Acts as a potent dopamine D1 and D2 receptor agonist in the central nervous system
Restores dopaminergic neurotransmission in the striatum, improving motor control
Rapidly reverses 'off' episodes of motor dysfunction in advanced Parkinson's disease
Bypasses gastrointestinal absorption and first-pass metabolism allowing quick onset of action
Modulates intracellular signaling pathways via dopamine receptor activation
Improves muscle stiffness and rigidity by enhancing dopaminergic tone
Exerts anti-parkinsonian effects with a subcutaneous injection route
Induces vasodilation peripherally which may contribute to hypotension
May cause CNS effects including sedation, hallucinations, and dyskinesia
Does not contain opioids despite the name similarity to morphine

Therapeutic Clinical Uses

Treatment of intermittent 'wearing-off' episodes in patients with advanced Parkinson's disease
Management of acute motor fluctuations unresponsive to oral dopaminergic therapy
Adjunct to levodopa therapy for rapid symptom relief during 'off' periods
Short-term rescue therapy for Parkinsonian 'off' episodes
Used in patients experiencing delayed or unpredictable responses to oral medications
Treatment option for patients unable to take oral Parkinson's drugs during 'off' states
Facilitates improved motor function in advanced stages of Parkinson’s disease
Provides symptomatic relief of rigidity, bradykinesia, and tremor during off states

Side Or Adverse Effects

Nausea and vomiting, especially during initiation and dose escalation
Orthostatic hypotension causing dizziness and risk of falls
Injection site reactions including pain, swelling, and irritation
Drowsiness and sudden sleep episodes during normal activities
Confusion, hallucinations, and other neuropsychiatric symptoms
Dyskinesia or worsening of pre-existing involuntary movements in approximately 24% of patients
Yawning and nasal symptoms such as runny nose
Uncontrolled muscle movements or twitching
Severe allergic reactions including rash and swelling of face or throat
Erection lasting more than 4 hours (priapism) requiring urgent care
Peripheral edema (swelling of hands or feet)
Cardiac arrhythmias or palpitations potentially related to QT prolongation
Increased compulsive behaviors such as gambling or increased sexual urges
Fatigue and decreased alertness
Potential for severe nervous system reaction manifesting as stiffness, high fever, and confusion

Precautions

Initiate treatment under healthcare supervision with antiemetic prophylaxis due to nausea risk
Regular monitoring of blood pressure to detect orthostatic hypotension
Avoid abrupt discontinuation to prevent withdrawal symptoms such as confusion and fever
Use cautiously in patients with cardiovascular disease including history of stroke or arrhythmias
Careful use in patients with electrolyte abnormalities (hypokalemia, hypomagnesemia)
Patients with a history of psychosis or mental illness require close observation for worsening symptoms
Advise patients to avoid driving or operating machinery until response is known due to sedation risk
Avoid use in patients with known sulfite allergy due to risk of hypersensitivity
Gradual dose titration recommended to minimize adverse effects
Avoid concurrent use with contraindicated drugs such as certain antiemetics (ondasetron, dolasetron, etc.)
Monitor for development of compulsive behaviors and report to healthcare provider
Use caution in elderly patients due to increased susceptibility to side effects
Pregnancy and breastfeeding use only if benefits outweigh risks
Educate patients on proper injection technique and rotation of injection sites

Warnings

Contraindicated with use of 5-HT3 antagonists like ondansetron, granisetron, palonosetron, dolasetron, or alosetron due to risk of severe hypotension and loss of consciousness
Potential for severe hypotension, especially post-dose, necessitating cardiovascular monitoring
Risk of sudden sleep episodes and severe drowsiness which can impair safety during activities
Possibility of severe allergic reactions including anaphylaxis
May cause QT interval prolongation and serious arrhythmias, particularly in patients with electrolyte imbalances or pre-existing cardiac conditions
Do not inject intravenously as this may cause severe adverse reactions
Risk of pathological compulsive behaviors such as gambling or hypersexuality associated with dopaminergic therapy
Withdrawal symptoms may occur if therapy is stopped abruptly, requiring gradual taper
Use caution with drugs that potentiate CNS depression
Beware of neuroleptic malignant syndrome-like reactions with abrupt withdrawal or dose modification

Contraindications

Hypersensitivity to apomorphine or any component of the formulation
Concurrent use with 5-HT3 receptor antagonists such as ondansetron, granisetron, dolasetron, palonosetron, and alosetron
Patients with significant cardiovascular disease or unstable cardiac status without close monitoring
Known sulfite sensitivity due to presence of sodium metabisulfite in formulation
Severe hypotension or orthostatic hypotension prior to treatment initiation
Patients with history of severe psychosis or uncontrolled mental illness
Use in pediatric patients due to lack of safety and efficacy data

Drug Interactions

Contraindicated with 5-HT3 antagonists (ondansetron, granisetron, dolasetron, palonosetron, alosetron) due to risk of severe hypotension
Additive hypotensive effects with antihypertensive drugs
Potentiation of CNS depressants including opioids, benzodiazepines, muscle relaxants, and sedative-hypnotics
Reduced efficacy when used with dopamine antagonists such as metoclopramide or antipsychotics
Potential interaction with nitroglycerin causing exacerbated blood pressure drops
Interactions with mood stabilizers and antipsychotics affecting dopaminergic neurotransmission
Drugs that alter hepatic metabolism may affect apomorphine clearance
Combination with alcohol increases risk of hypotension and sedation
Possibility of increased side effects when taken with other dopaminergic agents
Agents affecting electrolytes (potassium, magnesium) may increase cardiac risk

Preparations Of The Drug

Apokyn Injection Pen: sterile solution for subcutaneous use in a prefilled pen injector
Each pen contains apomorphine hydrochloride at concentrations calibrated in mL for dosing corresponding to mg doses
Single-use needles supplied for subcutaneous injection
Associated antiemetic medications recommended for co-administration during initiation